Medically reviewed by Stan Saji, PharmD, MBA, RPh — Written by Kaylea Swearingen, PharmD
The landscape of Alzheimer’s disease treatments has shifted dramatically. For nearly two decades, medications only managed symptoms, such as memory loss or confusion, without attacking the root cause of the disease.
Today, the focus has shifted to disease-modifying therapies that slow disease progression, along with new options for managing behavioral symptoms.
Disease-modifying drugs
Disease-modifying drugs are monoclonal antibodies designed to target and clear beta-amyloid plaques. These are toxic protein clumps that build up in the brains of people with Alzheimer’s disease.
They are approved for people in the early stages of the disease (mild cognitive impairment or mild dementia). Examples include:
- Donanemab (Kisunla): This drug was approved in 2024. It is a monthly IV infusion that was shown to slow cognitive decline by about 35% over 18 months. People may eventually stop treatment with Kisunla once their brain scans show their amyloid plaques have been cleared.
- Lecanemab (Leqembi): This drug was approved in 2023. Leqembi has been shown to slow the progression of the disease by about 27%. Leqembi is also available as a subcutaneous injection (injection under the skin) option under the name Leqembi Iqlik that people can self-administer at home. Leqembi can also be given as a monthly IV maintenance option after the initial plaque-clearing phase.
New options for behavioral symptoms
Alzheimer’s affects more than just memory; it can also cause profound behavioral changes. Historically, doctors used powerful, off-label antipsychotics to manage these changes, but safer options have emerged.
- Dextromethorphan-bupropion (Auvelity): This drug was recently approved specifically to treat agitation associated with Alzheimer’s disease. It is the first non-antipsychotic option for this symptom.
- Brexpiprazole (Rexulti): This drug is an atypical antipsychotic that is also approved specifically used to treat severe agitation associated with Alzheimer’s disease.
There is still a lot of research going on around Alzheimer’s disease. Here are a few examples of things on the horizon:
- Tau Protein Inhibitors: Tau protein forms tangles inside brain cells, increasing the likelihood of cell death. Tau-targeting therapies are being studied.
- GLP-1 Drugs: Researchers are studying whether GLP-1 medications, such as semaglutide, can protect the brain. Initial dataTrusted Source suggest they may reduce neuroinflammation and metabolic dysfunction in the brain.
- Blood-Based Biomarkers: Highly sensitive new blood tests, such as Lumipulse and Elecsys, may allow doctors to detect Alzheimer’s pathology. These tests can give people access to new, early-stage medications much faster.
Summary
If you or someone you care for has Alzheimer’s disease, talk with your doctor about what options are available. They can help recommend the best treatment options for you.
Disclaimer: While Healthline strives for factual, comprehensive, and current information, this article is not a substitute for a licensed healthcare professional’s expertise. Always consult a doctor before taking or discontinuing any medication. Drug information is subject to change and may not cover all uses, directions, precautions, warnings, interactions, reactions, or adverse effects. The lack of a warning does not guarantee a drug’s safety, effectiveness, or appropriateness for all patients or specific uses. Learn more about our approach to content integrity.
Disclaimer
Artificial Intelligence Disclosure & Legal Disclaimer
AI Content Policy.
To provide our readers with timely and comprehensive coverage, South Florida Reporter uses artificial intelligence (AI) to assist in producing certain articles and visual content.
Articles: AI may be used to assist in research, structural drafting, or data analysis. All AI-assisted text is reviewed and edited by our team to ensure accuracy and adherence to our editorial standards.
Images: Any imagery generated or significantly altered by AI is clearly marked with a disclaimer or watermark to distinguish it from traditional photography or editorial illustrations.
General Disclaimer
The information contained in South Florida Reporter is for general information purposes only.
South Florida Reporter assumes no responsibility for errors or omissions in the contents of the Service. In no event shall South Florida Reporter be liable for any special, direct, indirect, consequential, or incidental damages or any damages whatsoever, whether in an action of contract, negligence or other tort, arising out of or in connection with the use of the Service or the contents of the Service.
The Company reserves the right to make additions, deletions, or modifications to the contents of the Service at any time without prior notice. The Company does not warrant that the Service is free of viruses or other harmful components.
